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A B S T R A C T
The lungs have potential as a means of systemic drug delivery of macromolecules. Systemic delivery requires
crossing of the air-blood barrier, however with molecular size-dependent limitations in lung absorption of large
molecules. Systemic availability after inhalation can be improved by absorption enhancers, such as bile salts.
Enhancers may potentially interfere with the diﬀerent constituents of the lungs, e.g. the lung surfactant lining
the alveoli or the lung epithelium. We used two in vitro models to investigate the potential eﬀects of bile salts on
lung surfactant function (with the constrained drop surfactometer) and on the epithelium in the proximal air-
ways (with the MucilAir™ cell system), respectively. In addition, we measured direct eﬀects on respiration in
mice inhaling bile salt aerosols. The bile salts inhibited lung surfactant function at diﬀerent dose levels, however
they did not aﬀect the integrity of ciliated cells at the tested doses. Furthermore, the bile salt aerosols induced
changes in the breathing pattern of mice indicative of pulmonary irritation. The bile salts were ranked according
to potency in vitro for surfactant function disruption and in vivo for induction of pulmonary irritation. The
ranking was the same, suggesting a correlation between the interference with lung surfactant and the respiratory
response.
1. Introduction
Inhalation of therapeutic agents is essential for treatment of re-
spiratory diseases, where local delivery targets the molecules to the
diseased organ whilst limiting systemic exposure. Furthermore, in-
halation is promising as a means of systemic delivery of active phar-
maceutical ingredients (APIs), such as biomolecules. In this case fast
and eﬃcient absorption is essential. Drugs can be delivered to the
airways via dry powder aerosols, these typically contain excipients,
such as carriers. To optimize gas-exchange, the lungs have a large
surface area and a thin barrier between the air and the systemic cir-
culation. The lungs are however also designed as a barrier to foreign
substances as the continuous branching of the airways constitutes an
eﬃcient ﬁlter for particles entering the lungs. Generally, large particles
are retained in the upper/central airways, and removed by constant
upward movement by mucus covered ciliated cells, while smaller
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particles (< 2 μm in aerodynamic diameter) reach the respiratory re-
gion of the lungs, the alveoli and respiratory bronchioles (Pulliam et al.,
2007).
To enter the blood stream, APIs need to cross not only the alveolar-
capillary cell barrier, but also the layer of lung surfactant (LS) that
covers the alveolar epithelium. The movement of large biomolecules
across the air-blood barrier is restricted, where the quantity of the
biomolecule that transfers from the lung lumen to the blood is inversely
proportional to size. These larger molecules (deﬁned as> 40 kDa) will
predominantly be retained in the lungs and will not reach the systemic
circulation (Hastings et al., 2004; Pﬁster et al., 2014). To make inhaled
macromolecules systemically bioavailable, absorption enhancers can be
added to the formulation (Hussain et al., 2004). Identifying enhancers
that do not evoke adverse eﬀects on the respiratory tract will greatly
improve the potential for pulmonary drug delivery of systemically
acting APIs.
Development of new inhalation therapeutics is complex and attri-
tion during the development process has historically been high.
Analysis of the AstraZeneca drug portfolio between 2005 and 2010
showed that safety attrition of inhaled candidate drugs due to toxicity
to the respiratory system accounted for about 30% of the project clo-
sures related to adverse respiratory eﬀects (Cook et al., 2014). These
closures occurred relatively late in the development process, i.e. at the
stage of comprehensive regulatory GLP toxicology studies or during
clinical evaluation. The high rate of attrition highlights the lack of
available predictive in vitro and in vivo tools for screening for toxicity in
the respiratory tract. Absorption enhancers work by altering the local
physiology of the air-blood barrier and their invasive mode of action
may pose an especially high potential for induction of unwanted reac-
tions in the lungs. These eﬀects could include sustained alterations in
the mucus layer in the upper airways or opening of tight junctions
between epithelial cells, direct damage of epithelial cells by solubili-
zation of membrane phospholipids, or increased transfer of other bio-
molecules than the intended API.
In the present study we have focused on bile salts as enhancers for
systemic delivery of APIs via the lungs. Bile salts are amphipathic
cholesterol derivatives that increase the dispersion of lipids and facil-
itate their absorption by the intestinal mucosa in the small intestine.
Based on these properties, bile salts have been investigated for their
applicability as enhancers in inhaled formulations of peptide- and
protein-based drug formulations (Okumura et al., 1992; Komada et al.,
1994; Yamamoto et al., 1994; Bäckström et al., 1996; Yamamoto et al.,
1997; Griese et al., 1998; Herting et al., 2001; Johansson et al., 2002;
Gross et al., 2006; Lopez-Rodriguez et al., 2011). Our use of bile salts
was primarily related to a principle evaluation of the models, rather
than an exact characterization of dose-relationship for any speciﬁc
application.
The LS layer is the very ﬁrst barrier any inhaled substance meets in
the alveoli. This thin ﬁlm coats the respiratory regions of the lungs. The
LS lowers the surface tension at the air-liquid interface, but also pro-
vides some protection against hazardous inhaled substances (Zuo et al.,
2008). Under normal conditions, the surface tension changes during the
breathing cycle and makes breathing eﬀortless. However, if the LS is
damaged, the surface tension does not decrease during the expiratory
compression, and the alveoli may collapse and the respiratory
bronchioles ﬁll with liquid, making breathing labored. The bile salts
can potentially disrupt the structure of the LS ﬁlm and thereby poten-
tially inhibit its function.
Here we used the constrained drop surfactometer (CDS) to explore
the eﬀect of bile salts on LS function by exposing a drop of LS to in-
creasing amounts of the diﬀerent bile salts. This approach has pre-
viously been used in investigations of nanomaterials, pharmaceuticals
and impregnation products (Valle et al., 2014, 2015; Sørli et al., 2015a,
2017). Importantly disruption of LS function in vitro correlates strongly
with respiratory eﬀects in vivo for impregnation products (Sørli et al.,
2015b, 2017).
The eﬀect of bile salts was also assessed in a 3D human airway in
vitro model (MucilAir™), representative of the central airways.
Respiratory toxicity was evaluated by measuring cell viability and
barrier integrity by trans-epithelial electrical resistance (TEER) after
bile salt exposure. A reduction in TEER indicates that the epithelial
barrier integrity is disrupted by the test chemical. The model has earlier
been used to test compounds with known inhalation toxicity proﬁles,
where it was found that cell barrier integrity and viability were pre-
dictive of in vivo toxicity (Balogh Sivars et al., 2018).
Furthermore, we used measurements of breathing patterns in mice
to evaluate acute respiratory reactions to inhaled bile salts. Mice in
head-out plethysmographs were exposed to increasing aerosol con-
centrations of bile salts and their breathing pattern was compared to
baseline values. The method is a standard method for measuring airway
irritation, and has previously been used to test airway irritation po-
tential of industrial chemicals (Alarie, 1973; Nielsen et al., 2005).
As described above, bile salts may potentially be hazardous to the
airways. We therefore hypothesized that bile salts could cause inhibi-
tion of LS function in the CDS set-up, alter the TEER and viability of
lung epithelial cells and aﬀect the breathing pattern in mice at diﬀerent
doses. We furthermore hypothesized that the compounds could be
ranked according to toxicity and that the ranking in vitro and in vivo
would be correlated.
2. Materials and methods
2.1. Chemicals
The following chemicals were bought from Sigma-Aldrich: cadmium
chloride, dimethylsulfoxid (DMSO), Triton™ X-100, sodium taur-
ocholate, sodium glycocholate, sodium taurodeoxycholate and sodium
deoxycholate. The abbreviations, hydroxyl positions and structures of
the bile salts are summarized in Table 1. The concentration of bile salts
was below the critical micelle concentration (CMC) reported in the
literature for the in vitro experiments, and below or on the CMC for the
in vivo experiments (Reis et al., 2004; Monte et al., 2009). Micronized
lactose (Lactohale®300) was a kind gift from DFE pharma, (Goch,
Germany). MucilAir™ culture medium was purchased from Epithelix
Sàrl and PBS from Thermo Fisher.
Curosurf® (Chiesi, Parma, Italy) was used as a model LS for all the
experiments. It is made from solvent extracted minced porcine lung
tissue and contains ∼99% w/w phospholipids and 1% w/w hydro-
phobic surfactant-associated proteins (SP-B and SP-C) (Zhang et al.,
2011). Curosurf® was diluted to 0.5 mg/mL in a buﬀer containing 0.9%
NaCl, 1.5 mM CaCl2, and 2.5mM HEPES, adjusted to pH 7.0 (Valle
et al., 2015).
2.2. pH measurements
LS is sensitive to extreme pH (the optimal range is between pH 4
and 7) (Amirkhanian and Merritt, 1995). Bile salts were diluted in
water to a ﬁnal concentration of 1mg/mL. The pH of the solutions was
measured using pH indicator strips (Alkalit, Merck). The pH of all bile
salt solutions was between 5.5 and 6.
2.3. In vitro determination of lung surfactant inhibition in the CDS model
Inhibition of LS function in vitro was tested using the constrained
drop surfactometer (Sørli et al., 2015a; Valle et al., 2015) by exposing a
drop of LS to increasing amounts of the diﬀerent bile salts. A drop of LS
(Curosurf®, 10 μL of 0.5mg/mL) was placed on a hollow based pedestal
with a sharp edge, and was dynamically cycled at 20 cycles/min
and< 30% compression rate (baseline). The LS was cycled prior to
exposure to obtain a baseline value. Any baseline experiment with a
minimum surface tension> 5mN/m and compression> 35% was
discarded. Images were continuously taken of the drop and analyzed by
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axisymmetric drop shape analysis (ADSA) software (Yu et al., 2016).
The output was, among others, surface tension of the drop. The CDS
was kept at 37 °C inside a heating box.
The eﬀect of the bile salts (1 mg/mL) on LS function was tested in 2
ways: by injecting a bile salt solution into the cycling drop or by
spreading of the bile salt solution on top of the cycling drop as follows.
A drop of surfactant was cycled during the entire experiment. After a 15
sec baseline, 0.5 µL of bile salt solution was injected into the drop or
spread on the drop, respectively (see Fig. 1). A new injection/spreading
was repeated every 30 sec. After 12.5min of injection/spreading, the
drop was cycled for 7.5 min (i.e. each experiment took 20min). The
experiment was repeated 5 times for each bile salt and technique. The
dose of bile salt leading to persistent inhibition of LS function
(minimum surface tension > 10mN/m) was deﬁned as the inhibitory
dose, calculated as µg bile salt per mg LS. Lactose was used as negative
control and the experiments were done as for the bile salts. We have
previously shown that lactose does not inhibit LS function (Sørli et al.,
2015a).
2.4. 3D human airway in vitro model
Primary airway cells were acquired from human patients under-
going surgical lobectomy where the study was conducted according to
the declaration of Helsinki on biomedical research (World Health
Organization, 2001) and received approval from the local ethics com-
mission. The experimental procedures were explained in full and all
subjects provided informed consent. MucilAir™ (Epithelix Sàrl) airway
epithelia was reconstituted of a mixture of human tracheal and bron-
chial cells and cultured at the air liquid interface (ALI) in MucilAir™
culture medium (Epithelix Sàrl), in 24-well plates with 6.5-mm Trans-
well® inserts (Corning). At each sampling point, or every 2–3 days for
those wells not being sampled, the cell culture medium was changed.
NaTCA, NaGCA, NaTDCA and cadmium chloride were dissolved in
DMSO and diluted further in a buﬀered saline solution (0.9% NaCl,
1.25mM CaCl2, 10mM HEPES) to obtain a total concentration of 0.8%
DMSO (v/v). To mimic inhalation in vivo, bile salts and cadmium
chloride (10 µL) were applied daily on the apical surface of the
MucilAir™ cultures at 1, 10 and 100 μM and left to incubate for 6 h prior
to replacing with fresh medium. The procedure was repeated for a
period of 48 h and each treatment was run as four replicates for each
bile salt concentration.
Barrier integrity was assessed by measuring TEER as previously
described (Huang et al., 2017). Cell viability was determined by
quantitation of ATP in cell lysates at termination by CellTiter-Glo®
Luminescent Cell Viability Assay (Promega) according to the manu-
facturer’s instructions. Cadmium chloride and 1% Triton™ X-100 di-
luted in PBS (without MgCl2 and CaCl2) were used as positive controls.
Table 1
Name, abbreviation and structure of bile salts used.
Compound Abbreviation Position of hydroxyls Structure
Sodium taurocholate NaTCA 3α7α12α
Sodium glycocholate NaGCA 3α7α12α
Sodium taurodeoxycholate NaTDCA 3α12α
Sodium deoxycholate NaDCA 3α12α
Fig. 1. Examples of injection of bile salt solution into (left) and spreading of
bile salt solution on to (right) a drop of LS.
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2.5. Mouse bioassay
2.5.1. Animals
A total of 52 inbred BALB/cJ male mice aged 5–8weeks at arrival
were purchased from Taconic M&B (Ry, Denmark) and housed in
polypropylene cages (380x220x150 mm) furnished with aspen bedding
(Tapvei, Estonia), enriched with a mouse house (80-ACRE011,
Techniplast, Italy) and small aspen blocks (Tapvei, Estonia). The photo-
period was from 06:00 to 18:00, and the temperature was 21 °C and
relative humidity in the animal room was 55%. The inhalation ex-
posures were done between 09:00 and 15:00. Cages were sanitized
twice weekly. Food (Altromin no. 1324, Altromin, Lage, Germany) and
municipal tap water were available ad libitum. The mice were randomly
assigned to cages, 3–4 mice per cage, and acclimatized for a minimum
of one week. Mice from the same cage were used in the same experi-
ment.
2.5.2. Ethical statement
Treatment of the animals followed procedures approved by The
Animal Experiment Inspectorate, Denmark (Permissions No. 2014-15-
2934-01042-C2). All experiments were performed by trained personnel
and conformed to the Danish Regulations on Animal Experiments (LBK
nr. 474 af 15/05/2014 and BEK nr. 1589 af 11/12/2015), which in-
clude guidelines for care and use of animals in research. Anesthesia was
not used during the experiments, because the bioassay depends on the
animals being fully awake with uncompromised breathing. The ex-
posure was stopped if the tidal volume (VT) was reduced by > 30%
compared to baseline or after 1 h of exposure. The exact number of
Fig. 2. The average minute breathing pattern for tidal volume (VT, top row) and frequency (BPM, bottom row) plotted against the minute of the experiment for each
mouse in the experiment. During the ﬁrst 15min of an experiment the mice were breathing clean air. At 15min the bile salt exposure started and the ﬂow into the
aerosol generator was doubled every 15min. The calculated accumulated deposited dose in µg/kg bw (assuming 10% deposition and no clearance during the
exposure period) has been indicated above (top panel) or below (bottom panel) each exposure level, except when the aerosol concentration exceeded the measuring
range of the aerosol instrument (OPS) and the deposited dose could not be calculated (marked by NA). After exposure the mice breathed clean air for 15min before
the experiment was stopped. In the panels for NaDCA, one mouse reacted diﬀerently from the rest, it has been included in the analysis, but has been colored gray for
identiﬁcation. *, ** and *** indicate that the average mean is signiﬁcantly diﬀerent from the mean of the baseline with p < 0.05, 0.01 and 0.001 respectively. Linear
regression of the changes in breathing pattern over time were ﬁtted to the data sets and plotted as a red line. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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animals used to test the toxicity of each bile salt can be found in
Supplementary Table 1.
2.5.3. Generation of bile salt aerosols for mouse bioassay
Dry powder aerosol exposure was initially tried using a Rotating
brush generator (Seipenbusch particle engineering, Kuppenheim,
Germany), but the generator could not deliver stable aerosols
(Supplementary Fig. 1). Therefore the salts were dissolved in deionized
water at a concentration of 10mM (except NaDCA that was tested at
5mM), droplets were generated by a jet nebulizer (Wong and Alarie,
1982) and the water content was reduced by passage through a diﬀu-
sion drier (Diﬀusion Dryer 3062, TSI Inc., Shoreview, MN, USA), before
entering the 20 L mouse exposure chamber (Clausen et al., 2003) (see
Supplementary Fig. 2 for drying of aerosols). The drying of the bile salt
droplets produced stable aerosols, and the exposure concentration
could be increased stepwise in a reproducible manner (the relationship
between the infusion rate into the nebulizer and the particle con-
centration in the exposure chamber and reproducibility between 2 ex-
posures can be seen in Supplementary Fig. 3). As the bile salts were
diluted in water no vehicle control was included in the experiments to
limit the number of mice used for the assessment. Outlet air was passed
through a series of particle- and active coal-ﬁlters before the exhaust to
the atmosphere.
2.5.4. Aerosol exposure monitoring
The bile salt concentrations in the exposure chamber were mon-
itored by gravimetric ﬁlter sampling and by measurement of the aerosol
particle size distribution. Gravimetric ﬁlter sampling was done essen-
tially as described in the standard DS/EN 481 (Dansk Standard, 1994).
Shortly, aerosols were collected on pre-weighed Teﬂon ﬁlters
(Flouropore™ Membrane ﬁlters, pore size 0.45 µm, Millipore A/S,
Denmark) placed in a closed-face 25-mm cassette. Filter sampling was
done at the same time as the mice were exposed and for the whole
duration of the exposure period (45–60min). The aerosols were drawn
through the ﬁlter by an Apex2™ personal sampling pump (Casella,
Buﬀalo, USA) at a ﬂow rate of 2 L/min. The particle size distributions
were measured by NanoScan (TSI Inc., Shoreview, MN, USA; particles
ranging from 0.01 to 0.36 µm) and optical particle sizer (OPS, TSI Inc.,
Shoreview, MN, USA; particles from 0.32 to 10 µm). The aerodynamic
diameter of the majority of the generated particles was< 0.7 µm ac-
cording to the particle number size distribution. The relationship be-
tween the concentrations measured by aerosol sampling by Nanoscan
and OPS compared to the concentration calculated from ﬁlter sampling
can be found in Supplementary Fig. 4. In 3 cases, the concentration in
the chamber exceeded the upper capacity of the OPS (marked in Fig. 2
as “not applicable”, NA). These points were at the 4th and highest ex-
posure level for the study of NaGCA, NaTCA and NaTDCA.
The chamber concentrations calculated from bile salts collected on
ﬁlters were in most cases higher than estimated by the aerosol mea-
surements (Supplementary Fig. 4). This is likely because the con-
centrations became too high to be measured by the OPS at the highest
level of exposure. The aerosol concentration measured by NanoScan
and OPS were used to estimate the deposited dose at each exposure
level.
2.5.5. Calculation of deposited dose from aerosol concentrations
The estimated deposited doses in Fig. 2 are calculated by using the
following assumptions. Firstly, that all of the particles at each aerosol
concentration level could be inhaled deeply into the lungs, this is likely
as measurements made by NanoScan and OPS showed that the majority
of the particles were<0.7 µm in aerodynamic diameter. Secondly, that
10% of the inhaled particles deposited in the lungs of the mice, and
ﬁnally, that the deposited dose accumulated over the time of the ex-
posure. The estimated deposited dose was divided by the body weight
of the mouse resulting in a dose of x µg deposited bile salt per kg body
weight of the mouse (Fig. 2 and Table 3). To estimate the deposited
dose at each exposure level the aerosol concentration was multiplied
with the tidal volume, breathing frequency and duration of exposure.
This number was multiplied by 0.1, as a deposition of 10% was as-
sumed, and divided by the weight of the mouse. As we assumed that the
bile salts accumulated during the duration of exposure, the deposited
doses calculated for any previous exposure levels were added to the
calculated deposited dose.
2.5.6. Bile salt exposure in the mouse bioassay
To assess the acute eﬀects of bile salts on respiration, groups of mice
(n= 3–7, Supplementary Table 1) were placed in individual, head-out
plethysmograph tubes and exposed. First, a 15min baseline period was
recorded for each mouse while breathing clean air. Then, the mice were
exposed to the bile salt aerosol until the breathing pattern was aﬀected
(≥30% reduction of VT compared to baseline), or for a maximum of
60min. If the breathing pattern of the mice was aﬀected by the ex-
posure, the mice were exposed to clean air for 15min after end of ex-
posure, to assess for reversibility of the respiratory eﬀects. The lowest
observed adverse eﬀect dose (LOAED) was found by range-ﬁnding ex-
periments.
The range-ﬁnding experiments were done as follows: a group of
mice (n= 3–7) was exposed to increasing aerosol concentrations of the
bile salt in question. The start concentration was set based on data from
the CDS, i.e. NaDCA was tested at a lower start concentration than the 3
other bile salts. This was done to ensure that the ﬁrst concentration
would not cause acute lung eﬀects. The start concentration was used
during the ﬁrst 15min of exposure. If no eﬀect was observed at this
concentration, the infusion ﬂowrate was doubled every 15min. If no
eﬀect was observed after a total of 60min of exposure, a new group of
mice was used for a second range-ﬁnding experiment until the highest
concentration that could be generated in the system was reached. If no
eﬀect occurred during any of the range-ﬁnding experiments, the con-
centration of the bile salt solution was increased, i.e. NaTCA was sub-
sequently tested at a concentration of 30mM in the same dose-increase
setup until the LOAED was identiﬁed.
2.5.7. Collection of respiratory parameters
The Notocord Hem (Notocord Systems SA, Croissy-sur-Seine,
France) data acquisition software was used to collect and calculate
several mouse respiratory parameters. We used the tidal volume (VT,
mL), respiratory frequency (BPM, breaths/min), time of break (TB, ms),
time of pause (TP, ms), time of expiration (TE, ms), and time of in-
spiration (TI, ms). Comprehensive descriptions of the breathing para-
meters and their interpretation have been made elsewhere (Alarie,
1973; Vijayaraghavan et al., 1993; Larsen and Nielsen, 2000). Data
acquisition and calculations were performed as described previously
(Larsen et al., 2004).
2.5.8. Evaluation of acute respiratory eﬀects
Prior to exposing groups of mice to the bile salt aerosol, the mice
breathed clean air, only mice that had a stable baseline continued
through to the exposure phase of the experiment. To assess eﬀects re-
lated to exposure, the respiratory parameters during exposure were
compared to baseline levels, i.e. each mouse served as its own control.
For each mouse, the mean values of each minute during the experiment
were calculated and the change compared to baseline was calculated.
To estimate the eﬀect of each bile salt concentration the ﬁnal 10min of
each 15min period was plotted against the minute of exposure. The
accumulated deposited dose is indicated above each exposure period
(Fig. 2). Adverse eﬀect caused by the exposure to an aerosol of a bile
salt was deﬁned as a reduction in tidal volume (VT) to≤ 90% of
baseline (Fig. 2). A change of 10% compared to baseline was chosen
because this could be distinguished from changes to the respiration
caused by stress, e.g. induced by handling and restraint in the ple-
thysmograph. This reduction in VT coincided with an increase of
breathing frequency (BPM) (Fig. 2) and reduction of TE and TI (not
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shown) compared to baseline, resulting in the characteristic breathing
pattern: rapid shallow breathing (RSB). After the exposure stopped,
respiratory data was collected for 15min more as the mice were
breathing clean air to determine if the changes to respiration were re-
versible.
2.5.9. Statistical evaluation of respiratory data
The respiration parameter at each exposure level was graphed and
statistically analyzed using R (version 3.4.3). For each bile salt, changes
in tidal volume (VT) and breathing frequency (BPM) were expressed as
a percentage of the baseline value. Analysis of variance with pairwise
comparison and Bonferroni adjustment were performed to compare the
changes in breathing pattern for each dose compared to baseline. A
signiﬁcant diﬀerence between the breathing parameter at a speciﬁc
dose and baseline has been marked with 1, 2 or 3*, indicating a sig-
niﬁcant diﬀerence from the mean of the baseline of p < 0.05, 0.01 and
0.001 respectively (Fig. 2). Linear regressions of the changes in
breathing pattern over time were ﬁtted to the data set and plotted as a
red line in Fig. 2.
3. Results
3.1. In vitro determination of LS inhibition in the CDS model
The bile salts were tested for LS inhibition in vitro using the CDS
setup. The minimum surface tension was chosen as the endpoint.
Inhibition of LS function was deﬁned as an increase in the minimum
surface tension above 10mN/m that persisted over time. Each bile salt
was tested 5 times with each method (injection or spreading) (Table 2).
Lactose was included in the experiments as a negative control. The dose
for inhibition was calculated as µg bile salt per mg LS.
3.2. 3D human airway in vitro model
The barrier integrity as measured by TEER of the human lung epi-
thelial cell layer did not change after exposure (2 exposures over 48 h,
at 1, 10 or 100 µM) to NaTDCA, NaGCA or NaTCA. Moreover, the bile
salts did not alter the cell viability as measured by ATP in cell lysates.
3.3. Breathing pattern analysis in the in vivo mouse bioassay
Overall, the breathing patterns of the mice used for these experi-
ments were similar during baseline to those measured by other research
groups using the same setup and the same or other strains of mice
(Supplementary Table 2).
An adverse eﬀect of the exposure to an aerosol of a bile salt was
deﬁned as the onset of rapid shallow breathing (RSB). RSB was deﬁned
as reduction in tidal volume (VT) to ≤90% of baseline (Fig. 2). This
change coincided with an increase compared to baseline in breathing
frequency (BPM) (Fig. 2), time of expiration (TE), and time of in-
spiration (TI) (not shown). The accumulated deposited dose has been
indicated above each exposure level (µg/kg bw) in Fig. 2. With in-
creasing bile salt aerosol concentrations, the eﬀect on the breathing
parameters became larger, reaching a maximum of approximately 40%
reduction in VT and 40% increase in breathing frequency (Fig. 2). After
end of exposure the change to the breathing parameters reverted to-
wards baseline rapidly, however the baseline values were not reached
within the 15min recovery period (Fig. 2).
The dose that induced RSB in exposed mice was used to rank the bile
salts in vivo.
4. Discussion
The lungs have potential as route of delivery for systemically acting
biomolecules, but supplementation with absorption enhancers may be
needed. To our knowledge, there are currently no enhancers applied in
inhaled formulations and the intended interaction with the air-blood
barrier is associated with risks for adverse eﬀects. This could include
harmful impact on surfactant function and/or direct epithelial toxicity.
When identifying novel excipients and enhancers, it is highly desirable
to introduce model systems that can address some of these risks and
thereby enable exclusion of harmful substances at an early stage. In vitro
tests followed by acute in vivo tests addressing direct respiratory re-
sponses may identify the most harmful substances before they proceed
into more comprehensive in vivo assessment. In this investigation we
used two in vitro techniques that mimic two diﬀerent compartments and
toxicological targets in the lung that potentially could be aﬀected by
absorption enhancers, followed by assessment of acute eﬀects on re-
spiratory function in vivo. Firstly, we simulated the LS layer in the al-
veolar region by assessing how the LS function was aﬀected by our test
substances, four diﬀerent bile salt enhancers. Secondly, we recreated
the conductive airways by applying air-liquid interphase cultures and
exposed ciliated and mucus producing epithelial cells. Thirdly, we
studied in vivo whether acute airway responses in mice following in-
halation of enhancers correlated with the in vitro response and ranking.
We found that all the tested bile salts inhibited the LS function in
vitro. This allowed the bile salts to be ranked according to toxicity, and
this ranking was the same as for the in vivo eﬀects as assessed by the
dose that induced rapid shallow breathing (RSB). None of the bile salts
aﬀected the barrier integrity or viability of the air-liquid interphase
grown cells at the tested doses.
4.1. In vitro determination of lung surfactant inhibition in the CDS model
A drop of LS was exposed to bile salt solutions either by injecting
bile salt into the cycling drop or by spreading the solution onto
the cycling drop. The bile salts were ranked from the least to the
most inhibitory in almost the same order by both means of adminis-
tration; NaTCA < NaTDCA < NaGCA < NaDCA (by injection
NaTDCA=NaGCA), leaving NaDCA as the most potent inhibitor of LS
function. However, when the bile salt solution was spread onto the
cycling drop, inhibition generally occurred at higher doses than for
injection. For the least inhibitory bile salt, NaTCA, only 1 of 5 experi-
ments yielded an inhibition when it was spread onto the LS drop
(Table 3). These results suggest that the method of mixing aﬀects the
interaction of bile salt with the LS components and structures that exert
the surface tension lowering eﬀect. Also, structurally very similar
compounds (Table 1) had diﬀerent eﬀects on the surfactant function,
hence small changes in structure may have large eﬀects on the LS.
Further elucidation of these mechanisms would however require
methods that speciﬁcally study the interaction between the LS com-
ponents and bile salt, such as a CDS coupled to an atomic force mi-
croscopy (Valle et al., 2015). The pH of the dissolved salts was mea-
sured to exclude the possibility that the reaction was a result of
diﬀerent pH of the bile salts; it was shown that all the bile salt had
Table 2
Lung surfactant was exposed to 4 bile salts and lactose either by injection or
spreading to determine the dose that inhibited LS function (i.e. a persistent
change in minimum surface tension above 10mN/m).
Substance Injection Spreading
Inhibitory dose (µg/mg LS)
NaDCA 220 ± 45 300 ± 122
NaTDCA 360 ± 55 440 ± 207
NaGCA 360 ± 55 1140 ± 270
NaTCA 1100 ± 200 No inhibition*
Lactose No inhibition No inhibition
Data is given as (mean ± sd). *in 1 of the 5 repeats, LS was inhibited by the
highest dose of NaTCA (2500 µg/mg LS). The bile salts were ranked according
to the dose where a persistent inhibition occurred.
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similar pH in solution. Lactose was used as a control for both the in-
jection and spreading experiments as it is known to be extensively used
in marketed inhaled formulations (Sørli et al., 2015a). Lactose did not
inhibit the LS function by either mixing method, showing that the in-
hibition was not an eﬀect of injecting or spreading a foreign substance
into the cycling drop.
The interaction between bile salts and LS has been the focus on
several publications, because of the severe disease meconium aspiration
syndrome (MAS), which can aﬀect newborns aspirating stained am-
niotic ﬂuid during birth. The initial phase of MAS is characterized by
obstructed airways and LS inhibition, followed by a phase dominated
by airway inﬂammation (Lindenskov et al., 2015; Herting et al., 2001).
Meconium is the ﬁrst pass through the newborns digestive tract, and
among many other components it contains bile salts, approximately
0.005mg/mg meconium (Lopez-Rodriguez et al., 2011). Several groups
have investigated the eﬀect of meconium on LS function in vitro and
found the inhibitory bile salt dose to be between 0.07 and 20 µg/mg LS
(using the estimate of 0.005mg/mg meconium) (Bae et al., 1998; Moses
et al., 1991; Sun et al., 1993), i.e. much lower than the inhibitory doses
of pure bile salts found in this study (220–1100 µg/mg LS). Possibly,
components in the complex mixture of meconium work in synergy to
inhibit LS function, but the high variance in inhibitory dose may also
reﬂect the diversity in methods of detection, diﬀerences in LS pre-
paration, and meconium sampling. The mechanisms underlying in-
hibition of LS by meconium are not clear. Bae et al. (1998) observed
that meconium changed the ultrastructure of the LS from loosely
stacked layers to spherical lamellar structures. Lopez-Rodriguez et al.
(2011) suggest that bile salts can mobilize cholesterol into the air-liquid
interphase and thereby alters LS function. The surfactant preparation
used in the present study (Curosurf®) does however not contain cho-
lesterol and thus this is likely not the explanation for loss of function in
the present study.
4.2. 3D human airway in vitro model
The bile salts (NaTCA, NaGCA or NaTDCA) did not aﬀect the TEER
of human airway epithelial cells after 2 consecutive dosings over 48 h
with concentrations of up to 100 µM. These doses were selected in re-
lation to previous knowledge regarding measured lung concentrations
of inhaled agents in inhalation toxicology studies at doses causing lung
pathology (Balogh Sivars et al., 2018).
NaTCA has previously been used to enhance the transport of insulin
(approximately 6 kDa) across cells in vitro using Caco-2 cells grown on
trans-well inserts (Johansson et al., 2002). The authors found that when
the cells were exposed to concentrations between 20 and 30mM NaTCA
the TEER was low compared to cells exposed to lower concentrations,
but the cells survived and the insulin was transported across the cell
layer. Morimoto et al (Morimoto et al., 2000) used 10mM NaGCA to
enhance the permeation of insulin and thyrotropin-releasing hormone
across excised rabbit trachea. Both research groups used much higher
concentrations than those applied in the present setup.
Compared to the approximately 0.1 µm thick barrier between the air
and blood in the alveoli, the mucus covered ciliated cells of the upper
airways would be expected to present a much thicker and relatively
robust barrier to bile salts. Alveolar epithelial cells therefore would be a
more physiological relevant model for testing potential hazardous in-
teractions, however these cells are diﬃcult to obtain and to maintain
the alveolar epithelium phenotypes in vitro.
4.3. Breathing pattern analysis in the in vivo mouse bioassay
The mouse model explored in the present study has previously been
used to assess the acute sensory airway irritation potential of industrial
chemicals (Alarie, 1973; Nielsen et al., 2005) and is a standardized
method (ASTM International, 2012). The test assesses whether test
substances induce speciﬁc changes in the breathing pattern of mice
upon inhalation (Alarie, 1973). As the bile salts are dissolved in water
that is subsequently removed in the diﬀusion drier, there is no vehicle
control group of mice for these experiments, and the mice served as
their own controls. An adverse eﬀect of the exposure to an aerosol of a
bile salt was deﬁned as the onset of rapid shallow breathing (RSB), an
indicator of pulmonary sensory irritation. Pulmonary sensory irritation
is divided into 2 phases. The ﬁrst phase, P1, is characterized by rapid
shallow breathing and can be identiﬁed by an increase in breathing
frequency (BPM), in combination with a reduction of time of expiration
and inspiration (TE and TI, respectively) and tidal volume (VT) (Nielsen
et al., 1999). It can be followed by a second phase, P, which is char-
acterized by an increase in time of pause (TP). All the bile salts caused
signs of pulmonary sensory irritation, evident as induction of RSB, but
the eﬀect occurred at diﬀerent exposure levels. Elongation of TP was
seen rarely and only at the highest doses (not shown).
Pulmonary irritation has been studied with the same setup and
strain of mice for several chemicals, e.g. ozone (Nielsen et al., 1999;
Currie et al., 1998) and propranolol (Vijayaraghavan et al., 1993).
Ozone caused both P1 (RSB) and P (elongated TP) sensory irritation in
the same strain of mice used in this study (Nielsen et al., 1999). Currie
et al (Currie et al., 1998) found that RSB persisted 24 h after ozone
inhalation, and that ozone inhalation impaired LS function, caused by
water soluble proteins in the LS. Of note, ozone induces vascular
leakage and pulmonary edema (Nielsen et al., 1999). We did not per-
form histopathological evaluation of lungs from mice exposed to the
bile salts, however there was no persistent eﬀects on respiratory para-
meters (Fig. 2). The response to propranolol, on the other hand, is more
similar to that of the bile salts. Propranolol causes RSB in mice and
Guinea pigs (P phase) at lower doses and elongated TP (P1) at higher
doses, and the breathing pattern rapidly reverses to normal during the
recovery phase (Vijayaraghavan et al., 1993). The bile salts caused RSB
but only occasionally elongated TP at the highest dose level and after
45min exposure. As for propranolol, the breathing pattern rapidly re-
turned towards baseline during the recovery phase (Fig. 2).
Bile salts (an unspeciﬁed mix) have been studied as an enhancer for
inhaled insulin in humans. The human subjects inhaled a total of
1028 µg bile salt. There were no adverse events after the inhalation and
the mixture was well tolerated (Heinemann et al., 2000). Assuming that
30% of the inhaled powder reached the alveoli (Hirst et al., 2001;
Thorsson et al., 2001) and that the average person has 1000mg LS in
the lungs (Sørli et al., 2015a) this would result in a calculated dose of
0.31 µg bile salt/mg LS. At this dose, 1 bile salt (NaDCA) induced RSB in
our experiments when the dose was related to the amount of LS in mice
(Table 3). As we do not know which bile salts were in the inhaled
mixture it is diﬃcult to make further comparison. NaGCA has been
Table 3
Assuming that all particles of the aerosol were inhaled, that 10% deposited in
the lungs and that the bile salts accumulated during the duration of the ex-
posure, the lowest dose causing onset of rapid shallow breathing (RSB) was
calculated as µg/kg body weight. Using the same assumptions the dose was also
estimated in relation to the lung surfactant pool (µg/mg of LS). The estimation
of dose/amount of LS was based on the assumption that the mouse lung con-
tains approximately 0.15mg of LS.
Substance LOAED, accumulated deposited lung dose
Related to mouse weight (µg/kg
bw)*
Related to LS pool (µg/mg LS)
¤
NaDCA 0.88 0.12
NaTDCA 3.65 0.49
NaGCA 6.07 1.30
NaTCA 9.34 2.23
* Based on 10% deposition, ¤ based on 10% deposition and that a mouse has
0.15 mg LS. LOAED: lowest observed adverse eﬀect dose, LS: lung surfactant,
NaDCA: sodium deoxycholate, NaGCA: sodium glycocholate, NaTCA: sodium
taurocholate, NaTDCA: sodium taurodeoxycholate.
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studied as an enhancer for macromolecules (insulin or calcitonin), in
rats (Yamamoto et al., 1994, 1997; Okumura et al., 1992; Bäckström
et al., 1996; Morita et al., 1994). In all cases the bile salt enhanced
bioavailability. No adverse advents were observed, however, as the rats
were anesthetized during the exposure, eﬀects on the breathing pattern
would not have been possible to observe.
We have used LS function assessment in the CDS in combination
with mouse breathing pattern analysis while studying lung toxicity of
21 impregnation products (IP). The in vitro method could predict IP
toxicity in mice with 100% sensitivity and 63% speciﬁcity. However,
the toxicological proﬁle of the IPs in mice was qualitatively diﬀerent
from that of the bile salts. Toxic IPs induced a very rapid and steep
reduction in VT (Sørli et al., 2017) that has been shown to cause
spontaneous death if the mice are not immediately killed (Nørgaard
et al., 2010, 2014; Duch et al., 2014; Sørli et al., 2015b). In comparison
the mice exposed to bile salts rapidly recovered from the RSB when the
exposure was stopped, and they were allowed to breathe clean air for
15min (Fig. 2), after which they were killed. We can therefore not
exclude that there were long term eﬀects of the inhaled bile salts,
however, the immediate reversibility of the RSB supports that the
sensory irritation was transient and caused by interaction with LS.
4.4. Ranking and dose considerations
When the bile salts were ranked by their ability to inhibit LS func-
tion in vitro and their ability to induce RSB in exposed mice, the in vitro
and in vivo ranking was the same. Notably the assessment of LS function
in the CDS is cell-free, indicating that there may be a component of LS
interaction in the induction of RSB.
The dose per mg LS in the CDS in vitro system and per body weight
and in relation to the LS pool in the in vivo bioassay are presented in
Tables 2 and 3 respectively. It is apparent that the estimated dose
causing eﬀects on RSB is considerably lower than the dose estimate
from the in vitro CDS setup. However, caution should be taken in over
interpreting this diﬀerence; the CDS experiment is limited to in vitro
application and a selective measurement of surface tension, while an-
imals demonstrate a physiological response upon aerosol exposure.
There are aspects of exposure conditions, dose estimates, distribution
and concentration at site of action, which could contribute to this dif-
ference. In addition, in the lung, bile salts will interact with components
not represented in vitro, such as vagal nerve endings in the alveoli re-
gion. Atelectasis can activate the pulmonary stretch receptors (Alarie,
1973) and this presents a likely link between LS inhibition and RSB
onset in the animals. Nevertheless, the in vitro LS inhibition experiment
has the potential to rank the bile salts in the same order as the in vivo
experiment.
5. Conclusion
The ranking of the bile salts was the same when tested in vitro for LS
function in the CDS and the in vivomouse bioassay. Even if the bile salts
did not aﬀect the barrier integrity or viability of human airway epi-
thelial cells at the tested doses, it has earlier been proved to be a strong
tool for identifying hazardous substances, hence suggesting no overt
toxicity of bile salts on this cell type. The correlation between the
ranking by LS inhibition and the ranking of induction of RSB in vivo
strongly suggests that the physiological response is dependent upon LS
function in vivo.
These types of models can be applied to address plausible re-
spiratory liabilities with molecules like absorption enhancers, APIs or
other chemicals, with a potential to grade responses, but also to sepa-
rate direct and transient eﬀects on surfactant function from toxicity to
epithelial cells. Staging of the in vitro approaches can reduce the need
for experiments on animals and enhance selection of agents without
respiratory liabilities. Future research could include inclusion of mo-
lecules for which absorption enhancement is conﬁrmed to enable
assessment of potential separation between enhancing eﬀect and any
adverse consequence. Morphological evaluation of respiratory tissue
could also broaden the understanding of any consequence related to the
interaction with surfactant function.
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